bpc-157 human clinical evidence safety fda status Wolverine Stack: Healing Faster with Peptides BPC 157 Banned: Key Facts

Most available research comes from animal and laboratory studies

Nearly all (98.9%) identified businesses advertised semaglutide products, 40 (43.0%) advertised tirzepatide, 2 (2.2%) advertised liraglutide, 1 (1.1%) advertised retatrutide, and 1 (1.1%) advertised an unspecified GLP-1 product

PMC 10883429

## **Documentation requirements for J3475** As with any procedure, especially involving injecting drugs into patients, it's important to document the following before you file for a claim that includes this code: - The full name of the personnel who administered the injection + their credentials - The name and address of the facility where the injection was administered - The full name of the patient - The date(s) and time(s) of the drug administrations by injection - The exact dosage throughout the treatment, infusion details, and route - Blood test results showing magnesium levels - Patient records showing a diagnosis of complications that affect magnesium levels and information concerning related symptoms - Patient experience during and after the injection ## **Billing requirements for J3475** Besides the documentation requirements above, please note the following billing requirements for this HCPCS code: - They must reflect the dosage given over the course of the treatment